Last reviewed · How we verify

Capecitabine and aflibercept

John Strickler, M.D. · Phase 1 active Small molecule

Capecitabine and aflibercept is a Small molecule drug developed by John Strickler, M.D.. It is currently in Phase 1 development.

At a glance

Generic nameCapecitabine and aflibercept
SponsorJohn Strickler, M.D.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Capecitabine and aflibercept

What is Capecitabine and aflibercept?

Capecitabine and aflibercept is a Small molecule drug developed by John Strickler, M.D..

Who makes Capecitabine and aflibercept?

Capecitabine and aflibercept is developed by John Strickler, M.D. (see full John Strickler, M.D. pipeline at /company/john-strickler-m-d).

What development phase is Capecitabine and aflibercept in?

Capecitabine and aflibercept is in Phase 1.

Related